CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2018--
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today announced
that it will present a corporate overview at the ROTH Conference onMonday, March 12, 2018, at 2:30 p.m. PT in Orange County, CA.
A live webcast of the presentation may be accessed on the Investors
section of the Company’s website at www.kalvista.com.
An audio archive will be available on KalVista’s website for 30 days
following the presentation.
About KalVista Pharmaceuticals, Inc.
Pharmaceuticals, Inc. is a pharmaceutical company focused on the
discovery, development, and commercialization of small molecule protease
inhibitors for diseases with significant unmet need. The initial focus
is on inhibitors of plasma kallikrein, which is an important component
of the body’s inflammatory response and which, in excess, can lead to
increased vascular permeability, edema and inflammation. KalVista has
developed a proprietary portfolio of novel, small molecule plasma
kallikrein inhibitors initially targeting hereditary angioedema (HAE)
and diabetic macular edema (DME). The Company has created a structurally
diverse portfolio of oral plasma kallikrein inhibitors from which it
plans to select multiple drug candidates to advance into clinical trials
for HAE. KalVista’s most advanced program, an intravitreally
administered plasma kallikrein inhibitor known as KVD001, has
successfully completed its first-in-human study in patients with DME and
began a Phase 2 clinical trial in 2017.
For more information, please visit www.kalvista.com.
This press release contains
"forward-looking" statements within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "goal," "seek," "believe," "project,"
"estimate," "expect," "strategy," "future," "likely," "may," "should,"
"will" and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, available funding and
future clinical trial timing and results. Further information on
potential risk factors that could affect our business and its financial
results are detailed in the annual report on Form 10-K filed on July 27,
2017, our most recent Quarterly Report on Form 10-Q, and other reports
as filed from time to time with the Securities and Exchange Commission.
We undertake no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180305005016/en/
Source: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc.
Leah Monteiro, 857-999-0808
Corporate Communications & Investor Relations